TrumpRx launches to slash drug prices for cash-paying US patients
President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying patients. The…
06 Feb 2026
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
US Food and Drug Administration (FDA) Commissioner Marty Makary said the agency would target the mass-marketing of unapproved drugs amid ongoing opposition between drugmakers and online telehealth companies. In a…
06 Feb 2026
£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push
The London Cancer Hub, a key centre for the UK’s oncology research output, is undergoing a major expansion to increase laboratory and research space. Led by funding partner Aviva Capital…
06 Feb 2026
BMS reports flat revenue growth for full-year 2025
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024. The company's fourth quarter revenues increased 1% to $12.5bn, and its growth…
06 Feb 2026
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism. This contract enables Apotex to seek…
05 Feb 2026
Rare paediatric disease voucher programme makes long-awaited US return
After a lengthy period in regulatory limbo, the US Food and Drug Administration’s (FDA) rare paediatric disease priority review voucher (PRV) programme has returned to the pharma landscape, marking a…
05 Feb 2026
Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb
Japanese pharmaceutical giant Eisai has forged an oncology licensing deal worth up to $388m with Shanghai Henlius Biotech. Through this deal, Eisai will pay $75m up front for the rights…